Eur Heart J:预测早期乳腺癌患者心血管风险的评分体系

2019-12-31 不详 MedSci原创

本研究的目的旨在开发一个评分来预测早期乳腺癌(EBC)后主要心血管事件(MACE)的风险,以促进潜在的心脏毒性治疗和干预以减少心血管风险的个性化决策。本研究纳入了2003-2014年被诊断为EBC的患者,其中三分之二患者用于风险评分的推导;其余的用于验证,主要终点事件是急性心梗、不稳定性心绞痛、短暂性缺血发作、中风、周围血管疾病、心力衰竭或心血管死亡的复合事件。最终,有60294名EBC患者用于风

本研究的目的旨在开发一个评分来预测早期乳腺癌(EBC)后主要心血管事件(MACE)的风险,以促进潜在的心脏毒性治疗和干预以减少心血管风险的个性化决策。

本研究纳入了2003-2014年被诊断为EBC的患者,其中三分之二患者用于风险评分的推导;其余的用于验证,主要终点事件是急性心梗、不稳定性心绞痛、短暂性缺血发作、中风、周围血管疾病、心力衰竭或心血管死亡的复合事件。最终,有60294名EBC患者用于风险评分的推导,29810名患者用于验证。年龄、高血压糖尿病、缺血性心脏病、房颤心衰、脑血管疾病、外周血管疾病、慢性阻塞性肺疾病和慢性肾脏疾病与MACE发病率显着相关,并纳入评分。十年MACE发生率在得分最高的十分位患者中是得分最低的患者的40倍以上。

研究结果显示,EBC后心血管预后可根据患者治疗前的特点进行预测评估。

原始出处

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082521, encodeId=8de32082521a1, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 28 11:21:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357350, encodeId=3b1a135e3509e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563197, encodeId=048a156319ef6, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571192, encodeId=568815e1192f3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377628, encodeId=4a743e7628be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Dec 31 10:06:19 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2082521, encodeId=8de32082521a1, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 28 11:21:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357350, encodeId=3b1a135e3509e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563197, encodeId=048a156319ef6, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571192, encodeId=568815e1192f3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377628, encodeId=4a743e7628be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Dec 31 10:06:19 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2020-01-02 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=2082521, encodeId=8de32082521a1, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 28 11:21:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357350, encodeId=3b1a135e3509e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563197, encodeId=048a156319ef6, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571192, encodeId=568815e1192f3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377628, encodeId=4a743e7628be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Dec 31 10:06:19 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2020-01-02 slcumt
  4. [GetPortalCommentsPageByObjectIdResponse(id=2082521, encodeId=8de32082521a1, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 28 11:21:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357350, encodeId=3b1a135e3509e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563197, encodeId=048a156319ef6, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571192, encodeId=568815e1192f3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377628, encodeId=4a743e7628be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Dec 31 10:06:19 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2082521, encodeId=8de32082521a1, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Apr 28 11:21:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357350, encodeId=3b1a135e3509e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563197, encodeId=048a156319ef6, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571192, encodeId=568815e1192f3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Thu Jan 02 00:21:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377628, encodeId=4a743e7628be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Dec 31 10:06:19 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2019-12-31 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

相关资讯

Heart:男性与更大的胸主动脉直径呈独立相关

本研究的目的旨在提供55岁或55岁以上男性和女性胸主动脉直径的人群分布,并确定胸主动脉直径的决定因素。本研究纳入了2003-2006年2505名(1208名男性,平均年龄69.1±6.8岁)接受了非增强心脏CT检测的参与者,并在肺分叉水平对升主动脉(AA)和降主动脉(DA)的直径进行了测量。分析结果显示,男性的AA和DA直径明显大于女性,男性是更大的DA直径的独立相关因素(β 0.24, 95%

Heart:孤单与心脏病患者不良预后明显相关!

本研究的目的旨在评估孤单是否与缺血性心脏病、心律失常、心衰或心脏瓣膜疾病患者出院后的预后相关。本研究纳入分析了13443名缺血性心脏病、心律失常、心衰或心脏瓣膜疾病患者,并完成了调查随访,其中男性占70%,女性平均年龄是66.1岁,男性的平均年龄是64.9岁。分析结果显示,在不同的疾病种类中,孤单均与更差的预后相关,不论男性和女性。孤单可以预测患者的全因死亡率(男性:HR 2.92,95% CI

Eur Heart J:癌症患者的心血管疾病风险明显更高

本次观察性研究的目的旨在评估多个癌症中心患者的心血管疾病(CVD)死亡风险。本研究对正常人群和3234256名美国癌症幸存者(1973-2012年)进行了监测、流行病学和最终结果的比较。在28个癌症种类患者中,有1228328名患者(38%)死于癌症,365689名患者(11.3%)死于CVD。在死于CVD的患者中,有76.3%的患者是死于心脏病。在八个癌症中心,心血管疾病的死亡率风险在至少一个日

Eur Heart J:慢性系统性炎症是癌症的危险因素

血浆高敏C反应蛋白(CRP)的升高代表的低水平炎症反应是心血管疾病(CVD)的危险因素之一,同样也可能增加癌症的发表风险。本研究的目的旨在评估稳定性CVD患者低水平系统系炎症与癌症发生的相关性。本研究纳入分析了7178名稳定性CVD且血浆CRP≤10mg/L的患者,经过平均8.3年时间的随访,有1072名患者诊断为癌症,CRP水平与总体癌症发生率相关(HR 1.35; 95% CI 1.10-1.

Heart:心包脂肪含量与HIV患者不良的心功能相关

艾滋病毒携带者(PLHIV)改变了脂肪分布,增加了心力衰竭的风险,在这个人群中,心脏周围脂肪的数量和放射密度的改变是否与心功能不全有关尚不清楚。本研究的目的旨在评估HIV患者的心包脂肪(PCF)与心脏功能的相关性。本研究纳入分析了100例年龄>45岁且存在>1个传统心血管危险因素的HIV患者和100年龄和性别匹配的对照。与对照相比,PLHIV患者的BMI更低(27 vs 30, p=0.02),糖

Heart:艾森曼格综合征患者移植术后生存率研究

艾森曼格综合征(ES)患者心脏移植的最佳时间尚不清楚,本研究的目的旨在评估ES患者心肺移植(HLTx)或肺移植(LTx)后的生存率和移植相关死亡率。本研究纳入分析了1985-2012年714名ES患者,其中63名(9%)接受了移植手术。患者接受移植手术时的平均年龄为31.9岁,在移植后的30天内,有7名患者死亡(11%)。平均的生存时间是12年,1年、5年、10年和15年的总体生存率分别为84.1